Research on Burden of Disease for Patients With Myocardial Infarction Combining Dyslipidemia in China

Clinical Trial ID NCT03691246

Rank	Title	Journal	Year	PubWeight™‹?›
1	Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.	Lancet	2005	32.41
2	Future cardiovascular disease in china: markov model and risk factor scenario projections from the coronary heart disease policy model-china.	Circ Cardiovasc Qual Outcomes	2010	2.63
3	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR).	Atherosclerosis	2016	1.78
4	Baseline characteristics, management practices, and long-term outcomes of Middle Eastern patients in the Second Gulf Registry of Acute Coronary Events (Gulf RACE-2).	Ann Saudi Med	2011	1.27
5	Dyslipidemia prevalence, treatment, control, and awareness in the Canadian Health Measures Survey.	Can J Public Health	2013	0.95
6	Comparison of self-reported survey (SHIELD) versus NHANES data in estimating prevalence of dyslipidemia.	Curr Med Res Opin	2008	0.87
7	Prevalence and economic burden of cardiovascular diseases in France in 2013 according to the national health insurance scheme database.	Arch Cardiovasc Dis	2016	0.78
8	The Need for Brazil to Focus on CVD.	Glob Heart	2016	0.75